Which has preferable valuation and earnings, VCEL or IMVT?

Vericel has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 6.91 $16.52M $0.42 89.00 Immunovant N/A N/A -$505.61M -$2.78 N/A

Is VCEL or IMVT more profitable?

Vericel has a net margin of 7.35% compared to Immunovant's net margin of 0.00%. Vericel's return on equity of 6.41% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.35% 6.41% 4.61% Immunovant N/A -65.66% -59.88%

Does the media favor VCEL or IMVT?

In the previous week, Vericel had 2 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for Vericel and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.64 beat Vericel's score of 0.60 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, LNTH or VCEL?

Lantheus has higher revenue and earnings than Vericel. Lantheus is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.55B 4.22 $233.56M $4.15 24.15 Vericel $276.26M 6.91 $16.52M $0.42 89.00

Is LNTH or VCEL more profitable?

Lantheus has a net margin of 18.05% compared to Vericel's net margin of 7.35%. Lantheus' return on equity of 29.32% beat Vericel's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Vericel 7.35% 6.41% 4.61%

Does the media refer more to LNTH or VCEL?

In the previous week, Vericel had 2 more articles in the media than Lantheus. MarketBeat recorded 6 mentions for Vericel and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.65 beat Vericel's score of 0.60 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, VCEL or KYMR?

Vericel has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 6.91 $16.52M $0.42 89.00 Kymera Therapeutics $39.21M 164.12 -$311.35M -$3.57 N/A

Does the media favor VCEL or KYMR?

In the previous week, Kymera Therapeutics had 3 more articles in the media than Vericel. MarketBeat recorded 9 mentions for Kymera Therapeutics and 6 mentions for Vericel. Kymera Therapeutics' average media sentiment score of 0.75 beat Vericel's score of 0.60 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PTGX or VCEL?

In the previous week, Vericel had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for Vericel and 5 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.23 beat Vericel's score of 0.60 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, VCEL or SYRE?

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 6.91 $16.52M $0.42 89.00 Spyre Therapeutics $890K 7,325.78 -$155.20M -$2.08 N/A

Does the media prefer VCEL or SYRE?

In the previous week, Spyre Therapeutics had 2 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Spyre Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 0.60 beat Spyre Therapeutics' score of 0.26 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vericel (VCEL) Competitors

$37.38 +0.35 (+0.95%)

Closing price 04:00 PM Eastern

Extended Trading

$37.38 +0.00 (+0.01%)

As of 04:10 PM Eastern

Compare

VCEL vs. IMVT, LNTH, KYMR, PTGX, and SYRE

Should you buy Vericel stock or one of its competitors? MarketBeat compares Vericel with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vericel include Immunovant (IMVT), Lantheus (LNTH), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Vericel compare to Immunovant?

Vericel (NASDAQ:VCEL) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Vericel has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	6.91	$16.52M	$0.42	89.00
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Vericel presently has a consensus target price of $55.40, suggesting a potential upside of 48.21%. Immunovant has a consensus target price of $37.33, suggesting a potential upside of 19.73%. Given Vericel's stronger consensus rating and higher probable upside, analysts plainly believe Vericel is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Vericel has a net margin of 7.35% compared to Immunovant's net margin of 0.00%. Vericel's return on equity of 6.41% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Immunovant	N/A	-65.66%	-59.88%

47.1% of Immunovant shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vericel has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

In the previous week, Vericel had 2 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for Vericel and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.64 beat Vericel's score of 0.60 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Vericel beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Vericel compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Vericel had 2 more articles in the media than Lantheus. MarketBeat recorded 6 mentions for Vericel and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.65 beat Vericel's score of 0.60 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Lantheus shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 7.6% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lantheus has higher revenue and earnings than Vericel. Lantheus is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.22	$233.56M	$4.15	24.15
Vericel	$276.26M	6.91	$16.52M	$0.42	89.00

Lantheus has a net margin of 18.05% compared to Vericel's net margin of 7.35%. Lantheus' return on equity of 29.32% beat Vericel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Vericel	7.35%	6.41%	4.61%

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Vericel has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Lantheus currently has a consensus target price of $101.86, suggesting a potential upside of 1.61%. Vericel has a consensus target price of $55.40, suggesting a potential upside of 48.21%. Given Vericel's higher possible upside, analysts clearly believe Vericel is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Lantheus beats Vericel on 10 of the 16 factors compared between the two stocks.

How does Vericel compare to Kymera Therapeutics?

Vericel (NASDAQ:VCEL) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Vericel has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

Vericel has a net margin of 7.35% compared to Kymera Therapeutics' net margin of -611.94%. Vericel's return on equity of 6.41% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Vericel has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	6.91	$16.52M	$0.42	89.00
Kymera Therapeutics	$39.21M	164.12	-$311.35M	-$3.57	N/A

Vericel presently has a consensus target price of $55.40, indicating a potential upside of 48.21%. Kymera Therapeutics has a consensus target price of $117.14, indicating a potential upside of 49.73%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Kymera Therapeutics had 3 more articles in the media than Vericel. MarketBeat recorded 9 mentions for Kymera Therapeutics and 6 mentions for Vericel. Kymera Therapeutics' average media sentiment score of 0.75 beat Vericel's score of 0.60 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kymera Therapeutics beats Vericel on 8 of the 15 factors compared between the two stocks.

How does Vericel compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Vericel has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	147.81	-$130.15M	-$1.81	N/A
Vericel	$276.26M	6.91	$16.52M	$0.42	89.00

In the previous week, Vericel had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for Vericel and 5 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.23 beat Vericel's score of 0.60 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 7.6% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Protagonist Therapeutics currently has a consensus price target of $115.21, indicating a potential upside of 8.93%. Vericel has a consensus price target of $55.40, indicating a potential upside of 48.21%. Given Vericel's higher probable upside, analysts plainly believe Vericel is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Protagonist Therapeutics has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market. Comparatively, Vericel has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Vericel has a net margin of 7.35% compared to Protagonist Therapeutics' net margin of -154.88%. Vericel's return on equity of 6.41% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Vericel	7.35%	6.41%	4.61%

Summary

Vericel beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Vericel compare to Spyre Therapeutics?

Vericel (NASDAQ:VCEL) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	6.91	$16.52M	$0.42	89.00
Spyre Therapeutics	$890K	7,325.78	-$155.20M	-$2.08	N/A

Vericel has a net margin of 7.35% compared to Spyre Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.41% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Vericel has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vericel currently has a consensus target price of $55.40, indicating a potential upside of 48.21%. Spyre Therapeutics has a consensus target price of $91.33, indicating a potential upside of 21.65%. Given Vericel's higher probable upside, equities research analysts clearly believe Vericel is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Spyre Therapeutics had 2 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Spyre Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 0.60 beat Spyre Therapeutics' score of 0.26 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vericel beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCEL vs. The Competition

Export

Metric	Vericel	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.89B	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	89.00	18.83	24.65	23.63
Price / Sales	6.91	290.77	498.98	103.49
Price / Cash	66.66	120.20	43.05	54.72
Price / Book	5.33	8.00	10.43	6.70
Net Income	$16.52M	$23.89M	$3.56B	$337.26M
7 Day Performance	7.60%	-3.49%	-1.39%	-1.41%
1 Month Performance	11.72%	1.03%	0.86%	1.15%
1 Year Performance	-18.21%	34.39%	19.42%	22.61%

Vericel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCEL Vericel	3.4157 of 5 stars	$37.38 +0.9%	$55.40 +48.2%	-15.5%	$1.89B	$276.26M	89.00	300	News Coverage
IMVT Immunovant	3.7549 of 5 stars	$32.86 -1.3%	$37.33 +13.6%	+94.0%	$6.75B	N/A	N/A	120	Positive News
LNTH Lantheus	3.1809 of 5 stars	$97.13 -2.2%	$101.86 +4.9%	+20.1%	$6.47B	$1.55B	23.40	1,193
KYMR Kymera Therapeutics	2.3381 of 5 stars	$78.47 -3.6%	$118.10 +50.5%	+63.1%	$6.45B	$51.48M	N/A	170	News Coverage Analyst Forecast
PTGX Protagonist Therapeutics	1.8086 of 5 stars	$94.92 -4.7%	$115.21 +21.4%	+90.1%	$6.40B	$74.06M	N/A	120	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCEL) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vericel (VCEL) Competitors

VCEL vs. IMVT, LNTH, KYMR, PTGX, and SYRE

How does Vericel compare to Immunovant?

Summary

How does Vericel compare to Lantheus?

Summary

How does Vericel compare to Kymera Therapeutics?

Summary

How does Vericel compare to Protagonist Therapeutics?

Summary

How does Vericel compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vericel (VCEL) Competitors

VCEL vs. IMVT, LNTH, KYMR, PTGX, and SYRE

How does Vericel compare to Immunovant?

Which has preferable valuation and earnings, VCEL or IMVT?

Do analysts prefer VCEL or IMVT?

Is VCEL or IMVT more profitable?

Do institutionals & insiders hold more shares of VCEL or IMVT?

Which has more volatility & risk, VCEL or IMVT?

Does the media favor VCEL or IMVT?

Summary

How does Vericel compare to Lantheus?

Does the media refer more to LNTH or VCEL?

Do insiders and institutionals have more ownership in LNTH or VCEL?

Which has higher valuation and earnings, LNTH or VCEL?

Is LNTH or VCEL more profitable?

Which has more risk and volatility, LNTH or VCEL?

Do analysts recommend LNTH or VCEL?

Summary

How does Vericel compare to Kymera Therapeutics?

Which has more volatility and risk, VCEL or KYMR?

Is VCEL or KYMR more profitable?

Which has better valuation & earnings, VCEL or KYMR?

Do analysts prefer VCEL or KYMR?

Does the media favor VCEL or KYMR?

Summary

How does Vericel compare to Protagonist Therapeutics?

Which has preferable earnings & valuation, PTGX or VCEL?

Does the media favor PTGX or VCEL?

Do insiders and institutionals believe in PTGX or VCEL?

Do analysts recommend PTGX or VCEL?

Which has more volatility & risk, PTGX or VCEL?

Is PTGX or VCEL more profitable?

Summary

How does Vericel compare to Spyre Therapeutics?

Which has higher valuation & earnings, VCEL or SYRE?

Is VCEL or SYRE more profitable?

Which has more volatility and risk, VCEL or SYRE?

Do insiders & institutionals believe in VCEL or SYRE?

Do analysts recommend VCEL or SYRE?

Does the media prefer VCEL or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools